LUNG adenocarcinoma plasticity may drive progression and treatment resistance through TP53-linked developmental reprogramming, new data suggest.
A new analysis of non-small cell lung cancer identified dysregulated developmental programs as a key feature of lung adenocarcinoma biology, with branching morphogenesis activation emerging as a marker of poorer prognosis and treatment resistance. The findings point to a TP53 interferon axis that may help explain why some lung adenocarcinomas lose alveolar identity, acquire basal-like features, and become less responsive to targeted therapy or immune checkpoint blockade.
Developmental Programs Shape Lung Cancer Progression
The investigators examined two lung developmental programs, alveogenesis and branching morphogenesis, across transcriptomic datasets, single-cell RNA sequencing, multiplexed immunohistochemistry, murine models, and 3D organotypic cultures. Across non-small cell lung cancer samples, alveogenesis and branching morphogenesis showed inverse expression patterns.
In lung squamous cell carcinoma, alveogenesis suppression and branching morphogenesis activation were consistent but not prognostic. In lung adenocarcinoma, however, branching morphogenesis activation was heterogeneous and clinically meaningful. Across five lung adenocarcinoma cohorts totaling 1,646 patients, high branching morphogenesis activity was associated with significantly reduced 5-year overall survival, independent of disease stage and age. Single-cell analyses also showed increased activation in local and distant metastases.
TP53 Interferon Axis May Drive Resistance
TP53 pathway alteration appeared central to lung adenocarcinoma plasticity. TP53 mutations were enriched in branching morphogenesis high tumors, occurring in 66% of cases compared with 30% of branching morphogenesis low tumors. Mouse model analyses supported a functional role, showing that combined Kras activation and Trp53 deletion reduced alveogenesis and increased branching morphogenesis activation.
This plasticity also tracked with therapy resistance. In tyrosine kinase inhibitor treated lung adenocarcinoma samples, branching morphogenesis activation was higher in recurrent progressive disease than in partial response samples. In EGFR mutant disease, branching morphogenesis high samples had poorer disease-free survival after third generation EGFR inhibitor treatment. The signal also extended to immunotherapy, where branching morphogenesis high tumors had reduced progression-free survival despite features usually associated with immune checkpoint blockade response.
At the cellular level, branching morphogenesis activation reflected loss of alveolar type 2 lineage fidelity and acquisition of a basal-like phenotype. Type I interferon signaling promoted this phenotype in TP53-mutant lung adenocarcinoma cells grown in 3D culture, while TP53 wild-type cells showed the opposite response.
Together, the findings position lung adenocarcinoma plasticity as a potential prognostic and predictive biomarker, with implications for patient selection and future therapeutic strategies targeting developmental reprogramming.
Reference
Bienkowska KJ et al. Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma. Mol Oncol. 2026;doi:10.1002/1878-0261.70263.
Featured Image: Syda Productions on Adobe Stock.
